Cargando…

Adipose tissue measurement in clinical research for obesity, type 2 diabetes and NAFLD/NASH

INTRODUCTION: Excess body fat is linked to higher risks for metabolic syndrome, type 2 diabetes mellitus (T2DM), and cardiovascular disease (CV), among other health conditions. However, it is not only the level but also the distribution of body fat that contributes to increased disease risks. For ex...

Descripción completa

Detalles Bibliográficos
Autores principales: Vilalta, Adrian, Gutiérrez, Julio A., Chaves, SuZanne, Hernández, Moisés, Urbina, Silvia, Hompesch, Marcus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9094496/
https://www.ncbi.nlm.nih.gov/pubmed/35388643
http://dx.doi.org/10.1002/edm2.335
_version_ 1784705550039121920
author Vilalta, Adrian
Gutiérrez, Julio A.
Chaves, SuZanne
Hernández, Moisés
Urbina, Silvia
Hompesch, Marcus
author_facet Vilalta, Adrian
Gutiérrez, Julio A.
Chaves, SuZanne
Hernández, Moisés
Urbina, Silvia
Hompesch, Marcus
author_sort Vilalta, Adrian
collection PubMed
description INTRODUCTION: Excess body fat is linked to higher risks for metabolic syndrome, type 2 diabetes mellitus (T2DM), and cardiovascular disease (CV), among other health conditions. However, it is not only the level but also the distribution of body fat that contributes to increased disease risks. For example, an increased level of abdominal fat, or visceral adipose tissue (VAT), is associated with a higher risk of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). METHODS: A review of the most relevant primary and secondary sources on body composition from the last 25 years was conducted. Relevant articles were identified using PUBMED and Google Scholar. Narrative synthesis was performed as statistical pooling was not possible due to the heterogeneous nature of the studies. RESULTS: The body mass index (BMI) is commonly used as a proxy measure of body fatness. However, BMI does not reflect the level and distribution of body fat. Other anthropometric methods such as waist circumference measurement and waist‐hip ratio, as well as methodologies like hydro densitometry, bioelectrical impedance, and isotope dilution are also limited in their ability to determine body fat distribution. Imaging techniques to define body composition have greatly improved performance over traditional approaches. Ultrasound (US), computed tomography (CT), dual‐energy X‐ray absorptiometry (DXA), magnetic resonance imaging (MRI), are now commonly used in clinical research. Of these, MRI can provide the most accurate and high‐resolution measure of body composition. In addition, MRI techniques are considered the best for the determination of fat at the organ level. On the other hand, imaging modalities require specialized, often expensive equipment and expert operation. CONCLUSIONS: Anthropometric methods are suitable for rapid, high‐volume screening of subjects but do not provide information on body fat distribution. Imaging techniques are more accurate but are expensive and do not lend themselves for high throughput. Therefore, successful trial strategies require a tiered approach in which subjects are first screened using anthropometric methods followed by more sophisticated modalities during the execution of the trial. This article provides a brief description of the most clinically relevant adipose tissue measurement techniques and discusses their value in obesity, diabetes, and NAFLD/NASH clinical research.
format Online
Article
Text
id pubmed-9094496
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-90944962022-05-18 Adipose tissue measurement in clinical research for obesity, type 2 diabetes and NAFLD/NASH Vilalta, Adrian Gutiérrez, Julio A. Chaves, SuZanne Hernández, Moisés Urbina, Silvia Hompesch, Marcus Endocrinol Diabetes Metab Review Articles INTRODUCTION: Excess body fat is linked to higher risks for metabolic syndrome, type 2 diabetes mellitus (T2DM), and cardiovascular disease (CV), among other health conditions. However, it is not only the level but also the distribution of body fat that contributes to increased disease risks. For example, an increased level of abdominal fat, or visceral adipose tissue (VAT), is associated with a higher risk of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). METHODS: A review of the most relevant primary and secondary sources on body composition from the last 25 years was conducted. Relevant articles were identified using PUBMED and Google Scholar. Narrative synthesis was performed as statistical pooling was not possible due to the heterogeneous nature of the studies. RESULTS: The body mass index (BMI) is commonly used as a proxy measure of body fatness. However, BMI does not reflect the level and distribution of body fat. Other anthropometric methods such as waist circumference measurement and waist‐hip ratio, as well as methodologies like hydro densitometry, bioelectrical impedance, and isotope dilution are also limited in their ability to determine body fat distribution. Imaging techniques to define body composition have greatly improved performance over traditional approaches. Ultrasound (US), computed tomography (CT), dual‐energy X‐ray absorptiometry (DXA), magnetic resonance imaging (MRI), are now commonly used in clinical research. Of these, MRI can provide the most accurate and high‐resolution measure of body composition. In addition, MRI techniques are considered the best for the determination of fat at the organ level. On the other hand, imaging modalities require specialized, often expensive equipment and expert operation. CONCLUSIONS: Anthropometric methods are suitable for rapid, high‐volume screening of subjects but do not provide information on body fat distribution. Imaging techniques are more accurate but are expensive and do not lend themselves for high throughput. Therefore, successful trial strategies require a tiered approach in which subjects are first screened using anthropometric methods followed by more sophisticated modalities during the execution of the trial. This article provides a brief description of the most clinically relevant adipose tissue measurement techniques and discusses their value in obesity, diabetes, and NAFLD/NASH clinical research. John Wiley and Sons Inc. 2022-04-06 /pmc/articles/PMC9094496/ /pubmed/35388643 http://dx.doi.org/10.1002/edm2.335 Text en © 2022 The Authors. Endocrinology, Diabetes & Metabolism published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Articles
Vilalta, Adrian
Gutiérrez, Julio A.
Chaves, SuZanne
Hernández, Moisés
Urbina, Silvia
Hompesch, Marcus
Adipose tissue measurement in clinical research for obesity, type 2 diabetes and NAFLD/NASH
title Adipose tissue measurement in clinical research for obesity, type 2 diabetes and NAFLD/NASH
title_full Adipose tissue measurement in clinical research for obesity, type 2 diabetes and NAFLD/NASH
title_fullStr Adipose tissue measurement in clinical research for obesity, type 2 diabetes and NAFLD/NASH
title_full_unstemmed Adipose tissue measurement in clinical research for obesity, type 2 diabetes and NAFLD/NASH
title_short Adipose tissue measurement in clinical research for obesity, type 2 diabetes and NAFLD/NASH
title_sort adipose tissue measurement in clinical research for obesity, type 2 diabetes and nafld/nash
topic Review Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9094496/
https://www.ncbi.nlm.nih.gov/pubmed/35388643
http://dx.doi.org/10.1002/edm2.335
work_keys_str_mv AT vilaltaadrian adiposetissuemeasurementinclinicalresearchforobesitytype2diabetesandnafldnash
AT gutierrezjulioa adiposetissuemeasurementinclinicalresearchforobesitytype2diabetesandnafldnash
AT chavessuzanne adiposetissuemeasurementinclinicalresearchforobesitytype2diabetesandnafldnash
AT hernandezmoises adiposetissuemeasurementinclinicalresearchforobesitytype2diabetesandnafldnash
AT urbinasilvia adiposetissuemeasurementinclinicalresearchforobesitytype2diabetesandnafldnash
AT hompeschmarcus adiposetissuemeasurementinclinicalresearchforobesitytype2diabetesandnafldnash